Latest news & insights
Professor Alan Boyd appointed as Non-Executive Director at Clinigen Group
Boyds’ CEO, Professor Alan Boyd, has been appointed as a Non-Executive Director at global pharmaceutical and services company, Clinigen Group. Clinigen’s unique combination of businesses
Boyds presented with Queen’s Award for Enterprise
Boyds has been presented with one of the UK’s most prestigious business awards – The Queen’s Award for Enterprise, International Trade for Outstanding Short-Term Growth
Boyds to chair and present at TOPRA Symposium
This year’s TOPRA Symposium will take place this October in Stockholm and is held in partnership with the Swedish MPA. The three-day symposium will cover
Boyds shortlisted as an OBN Award finalist
Boyds has been shortlisted as a finalist in the Best Sector Support Organisation category at the 2018 OBN Awards. CEO and Founder, Professor Alan Boyd commented:
Boyds appoints Consultant Pharmaceutical Physician
Boyds is delighted to welcome Christine Smith as a Consultant Pharmaceutical Physician to support the clinical activities of the company and in particular supporting the
Clarification on the assessment of ATMPs
Boyds has welcomed the very timely final Regulation (EU) 2018/781 from the European Commission which describes the criteria to be used in the assessment of
Boyds recognised with prestigious Queen’s Award for Enterprise
Boyds has today been recognised with one of the UK’s most prestigious business awards – The Queen’s Award for Enterprise, International Trade for Outstanding Short
AMO Pharma announces results of Phase 2 proof-of-concept study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1
AMO Pharma Announces Results of Phase 2 Proof-of-Concept Study of AMO-02 in Congenital and Childhood Onset Myotonic Dystrophy Type 1 – Patients showed significant improvements
